Editorial coverage
Plain-English peptide writing. Fundamentals, safety, head to heads, and the mistakes new users actually make.
The fastest-growing peptides of 2026
US peptide searches now run past 10 million a month, and the curve is steepest for a handful of compounds. Here's what's actually surging, what the trial data says, and where the hype is ahead of the evidence.
The 7 mistakes new peptide users make in their first cycle
Most new users don't blow up dramatically. They just spend 8 weeks running a peptide poorly and conclude 'it didn't work.' Here are the seven most common reasons that happens, and how to avoid each one.
Does BPC-157 actually heal tendons? What the data says
The most popular peptide on the consumer market. Promises tendon, ligament, and gut healing. The evidence is more mixed than the marketing, and more interesting.
Tirzepatide vs Semaglutide: which actually works better in 2026?
Both are GLP-class. Both produce weight loss. The head to head trial data is finally enough to call it. Here's which one wins for which use case, and where the equation is more nuanced than the headlines suggest.
Are peptides safe? An honest answer.
Short answer: it depends entirely on the peptide, the dose, the source, and the user. The longer answer is what most articles dodge. Here's the real risk landscape.
What are peptides? A plain English explainer
Peptides are short chains of amino acids that act as biological signals. Here's what that actually means for the compounds people are running, and why the category is bigger than the headlines suggest.